Prime Medicine, Common Etf Z Score
PRME Etf | USD 3.30 0.04 1.20% |
Prime |
Prime Medicine, Common ETF Z Score Analysis
Prime Medicine,'s Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
Based on the company's disclosures, Prime Medicine, Common has a Z Score of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) family and about the same as Health Care (which currently averages 0.0) category. This indicator is about the same for all United States etfs average (which is currently at 0.0).
Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
All Next | Launch Module |
Fund Asset Allocation for Prime Medicine,
The fund invests 99.55% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Prime Medicine,'s investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Prime Fundamentals
Return On Equity | -1.14 | ||||
Return On Asset | -0.47 | ||||
Operating Margin | (259.48) % | ||||
Current Valuation | 298.55 M | ||||
Shares Outstanding | 131.16 M | ||||
Shares Owned By Insiders | 23.90 % | ||||
Shares Owned By Institutions | 62.31 % | ||||
Number Of Shares Shorted | 15.19 M | ||||
Price To Earning | 14.40 X | ||||
Price To Book | 2.28 X | ||||
Price To Sales | 541.04 X | ||||
Gross Profit | (86.72 M) | ||||
EBITDA | (193.76 M) | ||||
Net Income | (198.13 M) | ||||
Cash And Equivalents | 146.66 M | ||||
Cash Per Share | 6.39 X | ||||
Total Debt | 13.63 M | ||||
Debt To Equity | 0.18 % | ||||
Current Ratio | 6.70 X | ||||
Book Value Per Share | 1.49 X | ||||
Cash Flow From Operations | (165.41 M) | ||||
Short Ratio | 14.10 X | ||||
Earnings Per Share | (2.06) X | ||||
Target Price | 12.64 | ||||
Number Of Employees | 234 | ||||
Beta | 2.09 | ||||
Market Capitalization | 432.83 M | ||||
Total Asset | 193.85 M | ||||
Retained Earnings | (491.33 M) | ||||
Working Capital | 86.55 M | ||||
One Year Return | (0.31) % | ||||
Three Year Return | 3.82 % | ||||
Net Asset | 193.85 M | ||||
Equity Positions Weight | 99.55 % |
About Prime Medicine, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prime Medicine, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prime Medicine, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prime Medicine, Common based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.